The first implementation meeting took place on 1^st July and go live is scheduled for 30^th September. The three-month timeframe maintains BSI’s impressive track record in rapid turn arounds. Ms. Alli Galindo, Senior Clinical Research Associate at Cardiac Dimensions commented: “BSI’s staff have been excellent every step of the way throughout implementation. Working with us collaboratively on our needs, they provided thorough explanations of how their system meets our trial needs. Mostly, their quick responses and focused attention persuaded us they were excellent partners for our eTMF/CTMS. They’ve worked efficiently to meet tight implementation timeframes and set us up for success down the line. We look forward to a successful partnership between Cardiac Dimensions and BSI.”

Cardiac Dimensions is a leader in the development of minimally invasive treatments to address heart failure and related cardiovascular conditions. The privately held company is headquartered in Kirkland, Washington and has operations in the United States, Australia and Germany.

A rigorous evaluation of various CTMS providers was conducted, with the BSI solution winning out thanks to the easy-to-use user interface and the possibility to add own configurations over time.
“We vetted numerous possible vendors when selecting the provider for our CTMS, and BSI won out miles ahead of the competition. The BSI system not only offers seamless integration between their CTMS and eTMF products, but offered the choice of EDC integration as well. Understanding that our trial needs did not require all the capabilities of BSI’s solutions, the BSI team showed us several live demos and catered a proposal to our exact needs.

The possibility of starting out with the eTMF solution while knowing we will be able to easily expand with CTMS functionality through configuration, was extremely attractive to us. This way we avoid the effort and expense of a further full implementation, and the system can grow in parallel with our business,” said Ms. Galindo.

The flexibility of BSI’s approach has once again proved popular, giving customers the peace of mind that they are investing in a powerful suite of solutions that will meet their growing needs, while remaining cost effective.

“Companies such as Cardiac Dimensions, who may not yet require the full spectrum of what we offer, nevertheless want reassurance that simple, cost-effective expansion is possible as and when they need it,” explained Jan Nielsen, Community Manager Life Sciences at BSI. “We’re very pleased to be partnering with Cardiac Dimensions on this journey.”

About Cardiac Dimensions

Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatments to address heart failure and related cardiovascular conditions. Privately held, the company’s lead investors include Aperture Venture Partners, Arboretum Ventures, HostPlus, Life Sciences Partners, Lumira Ventures and M.H. Carnegie & Co. Cardiac Dimensions is headquartered in Kirkland, Washington and has operations in the United States, Australia and Germany.

Links: www.cardiacdimensions.com  www.bsi-lifesciences.com